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Abstract
Background: Changes in high sensitivity cardiac troponin-
T (hs-cTnT) concentrations may reflect either acute myo-
cardial injury or biological variation. Distinguishing 
between these entities is essential to accurate diagnosis, 
however, the biological variation of hs-cTnT in dialysis 
population is currently unknown. We sought to estimate 
the within- and between-person coefficients of variation 
of hs-cTnT in stable dialysis patients, and derive the criti-
cal difference between measurements needed to exclude 
biological variation with 99% confidence.
Methods: Fifty-five prevalent haemo- and peritoneal-dial-
ysis patients attending two metropolitan hospitals were 
assessed on 10 consecutive occasions; weekly for 5 weeks 
then monthly for 4 months. Assessments were conducted 
at the same dialysis cycle time-point and entailed hs-cTnT 
testing, clinical review, electrocardiography, and bio-
impedance spectroscopy. Patients were excluded if they 
developed clinical or physiological instability.
Results: In total 137 weekly and 114 monthly hs-cTnT 
measurements from 42 stable patients were analysed. 
Respective between- and within-person coefficients of 
variation were 83% and 7.9% for weekly measurements, 
and 79% and 12.6% for monthly measurements. Within-
person variation was unaffected by dialysis modality or 
cardiac co-morbidity. The bidirectional 99% reference 
change value was –25% and +33% for weekly measure-
ments, and –37% and +58% for monthly measurements.
Conclusions: The between-person variation of hs-cTnT in 
the dialysis population is markedly greater than within-
person variation indicating that hs-cTnT testing is best 
applied in this population using a relative change strat-
egy. An increase of 33% or a reduction of 25% in serial 
hs-cTnT concentrations measured at weekly intervals 
excludes change due to analytical and biological variation 
alone with 99% confidence.
Keywords: renal dialysis; troponin T; variability.
Introduction
Acute myocardial injury is a leading cause of hospitali-
sation and death in the dialysis population (9.8–16 per 
100-patient years), and cardiac troponins are among 
the most frequently requested tests in this group [1–5]. 
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A diagnosis of acute myocardial injury in dialysis patients 
is contingent on demonstrating a change in serial troponin 
concentrations in an appropriate clinical context [6, 7]. 
However, there is currently no evidence-based guidance 
on how much change in serial measurements discrimi-
nates between biological variation and acute myocardial 
injury leading to considerable diagnostic confusion [8].
Biological or within-person variation describes the 
random fluctuation of biomarker levels around a homeo-
static set-point in healthy individuals or those with stable 
disease, and is of no clinical significance [9]. Failure to 
accurately discriminate between changes in troponin 
concentrations caused by biological variation versus 
acute myocardial injury can result in unnecessary alarm, 
inappropriate management, and patient harm [10]. These 
concerns are particularly relevant following the recent 
introduction of high sensitivity cardiac troponin T (hs-
cTnT) assays which are able to detect small changes in cir-
culating concentrations [11]. Current guidelines either do 
not specify a magnitude of change in hs-cTnT concentra-
tions that excludes biological variation in dialysis patients 
[6, 8] or have developed theoretical recommendations 
based on the analytic performance of assays [7].
The aims of our study were to estimate the within- and 
between-person variation of hs-cTnT measured at weekly 
and monthly intervals from a cohort of stable dialysis 
patients and to use these estimates to calculate the per-
centage change between serial hs-cTnT measurements 
needed to exclude biological and analytic variation. We 
also sought to determine if the within-person variation 
of hs-cTnT differed according to cardiac co-morbidity or 
between dialysis modalities.
Materials and methods
Study design and patient recruitment
A prospective cohort study was conducted between October 2010 and 
April 2012 according to methods described by Fraser and Harris [12]. 
The study complied with the declaration of Helsinki and received 
ethics approval from the Metro-South Human Research Ethics Com-
mittee (HREC/10/QPAH/131).
Participants were recruited from the in-centre haemodialysis 
and peritoneal dialysis units of a tertiary-care teaching hospital in 
Brisbane, and a secondary-care hospital in Logan, Australia. Eligi-
ble participants identified from an electronic database of all patients 
receiving dialysis therapy were adults (aged  ≥  18-years) on mainte-
nance dialysis for  ≥  90-days who had a stable dialysis prescription 
for  ≥  30-days and a transthoracic echocardiogram  ≤  12-months prior 
to screening.
Eligibility criteria were chosen to ensure that the study cohort 
were physiologically and clinically stable at enrolment, and likely to 
remain stable for the duration of the study while still being repre-
sentative of the dialysis population. Patients were excluded if they 
had undergone coronary and/or valvular intervention or suffered 
a myocardial infarction or pulmonary embolism in the 6  months 
prior to screening; had echocardiographic evidence of severe pul-
monary hypertension, severe functional aortic and/or mitral valvu-
lar disease, or a left ventricular ejection fraction  < 30%; had been 
hospitalised for any indication in the 30-days prior to screening; 
had been commenced on or undergone a dose change of a diuretic, 
β-blocker, aldosterone receptor antagonist, angiotensin convert-
ing enzyme inhibitor or angiotensin type-1 receptor blocker in the 
30  days prior to screening; had experienced worsening angina, a 
new cardiac arrhythmia or undergone a dose change of associated 
therapies in the 30 days prior to screening; had a contraindication 
to bioimpedance measurement including a pacemaker, implantable 
cardiac defibrillator, joint replacements, or mechanical heart valve; 
were pregnant; had advanced malignancy; or were unable to provide 
informed consent.
Patient assessment
Patients were assessed on 10 consecutive occasions – weekly for 
5 weeks then monthly for another 4 months. All assessments were 
conducted between 6 and 8 AM, prior to the mid-week dialysis 
 session for haemodialysis patients, and between 8 and 10 AM on 
the same weekday for peritoneal dialysis patients. Patients avoided 
strenuous exercise prior to assessment.
Several factors affect hs-cTnT concentrations including extra-
cellular volume [13], cardiac rhythm [14], myocardial ischaemia 
[15], and the dialysis prescription [16, 17]. These influences were 
assessed using a structured clinical interview, physical examina-
tion and medical records review to ascertain interim hospitalisation, 
changes to medication and/or the dialysis prescription. The Cana-
dian Cardiovascular Society Angina Grading Scale [18] was used to 
assess change in cardiac ischaemic symptoms and the Truncated 
Framingham Heart Failure Score [19] was used to assess for evidence 
of pulmonary oedema at time of review. Patients also underwent a 
standard 12-lead electrocardiogram and whole body, multi-frequency 
bioimpedance analysis using the Body Composition Monitor BCM® 
(Fresenius Medical Care, Asia-Pacific) at each visit to measure intra- 
and extra-cellular volume. This instrument has a detection limit for 
change in extracellular volume of 0.87 L ± 0.64 L [20, 21].
Specimen collection, storage and analysis
hs-cTnT concentrations were measured at baseline then at weeks 
1–4 and months 2–4, providing data for four consecutive weekly and 
monthly intervals. To ensure that changes in hs-cTnT concentrations 
during the final measurement interval did not reflect changes in sub-
clinical risk, patients were also assessed for stability at week 5 and 
month 5.
Blood collected in lithium-heparin tubes was centrifuged and 
plasma separated within 1  h of collection. Plasma was stored at 
–80  °C until assayed. Hs-cTnT has been shown to be stable under 
these conditions [22].
All samples were batched and analysed together in a single 
analytic-run in random duplicate by a single expert operator using 
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a single instrument, and a single batch of reagent, control, and 
calibrators. Plasma hs-cTnT concentrations (nanograms per litre) 
were measured on the Cobas e170 instrument using the troponin-T 
hs kit (Roche Diagnostics, Australia); a monoclonal antibody elec-
trochemiluminescence assay which has a reported detection range 
of 5–10,000 ng/L. The population 99th centile reference limit for the 
assay is 14 ng/L [11].
Statistical analysis
Based on a ratio of analytic to within-person variation of  < 0.5 for hs-
cTnT, we estimated that a study sample of 40 patients undergoing 
hs-cTnT testing on eight occasions over four weekly and monthly 
intervals would have power  = 1.0 to estimate the within-person coef-
ficient of variation with a 95% confidence interval of  ± 1.9% [23]. A 
sample size of 55 was chosen to allow for dropouts and exclusions 
due to instability.
Patients were deemed to be unstable if between study visits they 
underwent a change in dose of diuretic, β-blocker, aldosterone recep-
tor antagonist, angiotensin converting enzyme inhibitor or angioten-
sin type-1 receptor blocker; a change in severity of cardiac ischaemic 
symptoms, dose of anti-anginal agents, or cardiac intervention; 
a change in anti-arrhythmic agent or new cardiac arrhythmia; a 
change in extracellular volume  > 1 L on bioimpedance analysis; a 
change in dialysis modality or prescription; hospitalisation for any 
reason or exhibited pulmonary oedema defined as a score  ≥  2 on 
the Truncated Framingham Heart Failure Score [19]. If a study par-
ticipant was deemed to be unstable, the hs-cTnT concentrations from 
the intervals preceding and following the event were excluded from 
the statistical analysis.
Normally distributed variables are summarised as mean ± stand-
ard deviation, and non-normally distributed variables as median 
and interquartile range. Hs-cTnT concentrations were logarithmi-
cally transformed for the variation analyses. We fitted mixed-effects 
models with random intercepts to calculate the between-person coef-
ficient of variation (CVG), the within-person coefficient of variation 
at weekly and monthly intervals (CVI) and the within-run analytic 
coefficient variation (CVA). Outlying variances were excluded using 
the Reed and Cochran tests, and linear regression analysis was used 
to exclude participants who demonstrated a consistent trend in hs-
cTnT concentrations in either direction which may reflect a change 
in subclinical risk.
The cohort was also divided into subgroups according to ischae-
mic heart disease status, severity of left ventricular diastolic dysfunc-
tion, presence or absence of left ventricular systolic dysfunction, 
quartiles of hs-cTnT concentrations at enrolment, and by dialysis 
modality. CVI was estimated for each subgroup and compared using 
Bartlett’s test. Ischaemic heart disease was defined as one or more 
of inducible ischaemia on non-invasive cardiac testing and/or  ≥  50% 
stenosis in  ≥  1 epicardial coronary artery on coronary angiography 
and/or a history of myocardial infarction. Left ventricular diastolic 
dysfunction was graded as absent, mild, moderate or severe accord-
ing to an established algorithm using echocardiographic measure-
ments [24]. Left ventricular systolic dysfunction was defined as a left 
ventricular ejection fraction  ≤  50% using Simpson’s rule [24].
The index of individuality (IOI) was calculated as CVI/CVG. This 
ratio gives an indication of whether a biomarker is best used within a 
relative-change monitoring strategy (IOI  < 0.6) or a reference interval 
strategy (IOI  > 0.6). The bidirectional reference change value (RCV) 
Assessed for eligibility (n=138)
Enrolled (n=55)
Completed weekly visits (n=50)
Not satisfying inclusion criteria (n=73)
Declined to participate (n=10)
Withdrew consent (n=2)
Withdrew after baseline visit (n=3)
   • Renal transplant (n=1)
   • Change in dialysis modality (n=2)
Select intervals excluded due to change in
extracellular volume >1L between visits
   • 51 monthly intervals
   • 36 weekly intervals
Included in final analysis:
   • 136 weekly intervals from 42 patients
   • 113 monthly intervals from 39 patients
Patients excluded entirely from final
analysis (n=7)
   • Hospital admission (n=3)
   • Cardiac arrhythmia (n=3)
   • Increase in severity of angina (n=1)
Renal transplant following completion of
weekly visits (n=2)
Completed monthly visits (n=48)
Figure 1 Flow diagram of patients assessed for eligibility, enrolled 
and analysed in the study.
was calculated according to the method described by Fokkema et al. 
[25] for logarithmically transformed data as = exp(–Z × √2 × σ) and 
exp(+Z × √2 × σ); where σ = √ln(CVI2+1) and Z is the Z-score of a standard 
normal distribution corresponding to a given probability.
Results
Patient characteristics
Details of the number of patients assessed, enrolled and 
included in the final analysis are shown in Figure 1. In total 
55 patients were recruited from the haemodialysis (n = 28) 
and peritoneal dialysis units (n = 27) of the participating 
institutions and their baseline characteristics are sum-
marised in Table 1. Cardiovascular risk factors, including 
hypertension (100%), diabetes mellitus (40%), and current 
or former smoking (51%) were highly prevalent. A substan-
tial proportion of the cohort also had evidence of established 
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cardiovascular disease including ischaemic heart disease 
(22%), left ventricular diastolic (87%) and/or systolic (9%) 
dysfunction, and peripheral- and/or cerebro-vascular 
disease (9%). Baseline hs-cTnT concentrations demon-
strated a right-skewed frequency distribution with a median 
of 34 (interquartile range 24–54) ng/L. A total of 90% of the 
study cohort had a hs-cTnT concentration exceeding the 
99th centile upper reference limit of the hs-cTnT assay [11].
Weekly and monthly variation of hs-cTnT
Seven patients and their corresponding hs-cTnT meas-
urements were excluded due to hospital admission 
Table 1 Baseline characteristics of the study cohort.
Characteristic   Value, n = 55
Male gender, %   45
Age
 Mean ± SD, years   59 ± 15
 Age distribution, %
  18–49 years   33
  50–69 years   40
  70–79 years   22
  80–90 years   5
Haemodialysis, %   51
Time on dialysis, months   35 (16–58)
Body mass index, kg/m2   30.2 (28.5–34.6)
Ratio of extracellular to total body water   0.48 ± 0.04
Systolic blood pressure, mmHg   130 ± 15
Diastolic blood pressure, mmHg   74 ± 12
Diabetes mellitus, %   40
Current or former smoker, %   51
Ischaemic heart disease, %   22
Peripheral- and/or cerebro-vascular disease, %   9
Left ventricular ejection fraction
 Mean ± SD, %   60 ± 7
 Left ventricular systolic dysfunction, %   9
Diastolic dysfunction, %
 Nil   13
 Mild   24
 Moderate   45
 Severe   18
Antihypertensive agents
 Median number of anti-hypertensive agents   1 (1–2)
 Proportion on β-blocker, %   42
 Proportion on ACE-I or ARB, %   38
hs-cTnT, ng/L
 Median (IQR)   34 (24–150)
 Minimum   8
 Maximum   241
  Proportion of sample (%) with baseline hs-cTnT 
concentration  > 14 ng/L
  90%
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin 
type-1 receptor blocker.
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Figure 2 Variation of high sensitivity cardiac troponin T (hs-cTnT) 
concentrations measured from each of the stable participants over 
the weekly and monthly follow-up phases.
(n = 3), paroxysmal atrial fibrillation (n = 3), and escalat-
ing anginal symptoms (n = 1). In addition, 36 weekly and 
51 monthly hs-cTnT sample-pairs were excluded due to a 
change in extracellular volume of  > 1 L between consecu-
tive visits. Hs-cTnT measurements performed over 136 
weekly intervals from 42 patients and 113 monthly inter-
vals from 39 patients were included in the final analysis. 
These data are shown in Figure 2 with excluded measure-
ments represented by gaps.
The respective analytic, within-person, and between-
person coefficients of variation of hs-cTnT were 3.1%, 
7.9%, and 83% for weekly intervals, and 2.4%, 12.6%, 79% 
for monthly intervals (Table 2). Between person variation 
was much greater than within-person variation (Figure 3), 
yielding low indices of individuality of 0.10 and 0.16 for 
the weekly and monthly intervals, respectively (Table 2).
Weekly and monthly reference change values for the 
80%, 90%, and 99% degrees of statistical confidence are 
shown in Table 2. Thus, hs-cTnT concentrations measured 
at weekly intervals needed to increase by 33% or fall by 
25% to ensure with 99% confidence that the observed 
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change exceeded analytic and biological variation alone. 
Monthly reference change values were larger than weekly 
values for a given degree of statistical confidence.
The within-person co-efficient of variation did 
not differ significantly between dialysis modalities, by 
ischaemic heart disease status, by severity of diastolic 
dysfunction or across quartiles of hs-cTnT concentration 
(Table 3). The effect of left ventricular systolic dysfunction 
on within-person variation was unable to be meaningfully 
analysed as only one such patient was retained in the final 
analysis after the exclusion of unstable patients.
Discussion
This study demonstrated that the between-person varia-
tion of hs-cTnT across the dialysis population was large 
and markedly greater than within-person variation for 
both the weekly and monthly measurement intervals 
(83% vs. 7.9%, and 79% vs. 12.6%, respectively). This 
Table 2 Estimates of variance components of high sensitivity troponin-T, bidirectional reference change values for stated degrees of statis-
tical confidence and index of individuality over weekly and monthly intervals for stable study participants.
 
 
Coefficient of variation, %  Reference change value 
 
Index of 
individuality
Analytic, 
CVA
  Between-
person, CVG
  Within-
person, CVI
99%  90%  80% CVI: CVG
Weekly   3.1  83  7.9  –25% and +33%  –17% and +20%  –13% and +15%  0.10
Monthly   2.4  79  12.6  –37% and +58%  –25% and +34%  –20% and +25%  0.16
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Figure 3 Box-plot of median (horizontal line), upper and lower 
quartiles (large rectangle), and range (whiskers) of high sensitivity 
cardiac troponin T (hs-cTnT) concentrations for each of the stable 
participants during the weekly follow-up phase.
Table 3 Within-person coefficients of variation of high sensitivity 
cardiac troponin-T (mean and 95% confidence intervals) by sub-
groups of dialysis modality, ischaemic heart disease status, cardiac 
diastolic function and quartiles of high sensitivity cardiac troponin-T 
concentration (hs-cTnT).
Sub-group   Weekly within-person 
coefficient of variation 
CVI% (95% CI)
  p-Value
Dialysis modality
 Peritoneal dialysis   7.5 (6.2–9.0) 
 Haemodialysis   8.2 (6.8–10.0)  0.68
Ischaemic heart disease
 Absent   5.7 (4.5–7.3) 
 Present   8.5 (7.3–9.9)  0.90
Diastolic dysfunction
 Nil/mild   8.2 (6.8–9.9) 
 Moderate/severe   7.7 (6.4–9.3)  0.78
hs-cTnT concentration, ng/L
 1st quartile (8–24)   10.3 (7.8–13.4) 
 2nd quartile (25–34)   8.3 (6.5–10.7) 
 3rd quartile (35–54)   6.3 (4.6–8.8) 
 4th quartile (55–241)   5.6 (4.5–7.1)  0.31
was reflected in the low index of individuality and indi-
cates that hs-cTnT measurements from dialysis patients 
are best interpreted by comparing serial measurements 
to each other rather than by comparing single values to 
a reference interval or a threshold value [26]. These find-
ings support current recommendations on interpreting 
troponin concentrations measured from dialysis patients 
[6, 7].
Interpreting serial hs-cTnT concentrations 
in dialysis patients
We found that the within-person coefficients of varia-
tion of hs-cTnT in stable dialysis patients were 7.9% and 
12.6% for the weekly and monthly measurement intervals, 
respectively. Using these values we calculated bidirec-
tional reference change values for pre-specified degrees of 
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statistical confidence (Table 2) [25]. The weekly 99% refer-
ence change value was +33% and –25%, indicating that 
hs-cTnT concentrations must increase by at least 33% or 
fall by 25% in the short term to exclude change due to bio-
logical and analytic variation alone with 99% certainty. 
We suggest that this short-term reference change value 
has the greatest relevance to clinical practice where tro-
ponin is measured over hours or days to diagnose acute 
myocardial injury. In addition, we suggest using the 99% 
level of statistical confidence as therapies that may be 
instituted after excluding biological variation carry risks 
of serious adverse events necessitating a high degree of 
certainty. It is also important to highlight that acute myo-
cardial injury may result from either coronary or non-cor-
onary aetiologies [6] and that careful clinical assessment 
remains imperative to determining the underlying cause 
of acute myocardial injury and to guide its management. 
We recommend using a relative (e.g., 33%) rather than 
absolute (e.g., 5–7 ng/L) change criterion as the former has 
been shown to be diagnostically superior in populations 
where the majority of individuals have a baseline hs-cTnT 
concentration exceeding the upper reference limit of the 
assay used and where the between-person variation of 
hs-cTnT is large, both of which have been demonstrated 
in this study [27].
Explicit guidance on the interpretation of serial tro-
ponins measured from dialysis patients is necessary as the 
distinction between troponin fluctuations resulting from 
biological variation versus those occurring during acute 
coronary syndromes, particularly non-ST elevation myo-
cardial infarction, is frequently unclear [28, 29]. To date, 
consensus guidelines on the interpretation of serial tro-
ponin measurements in dialysis patients have either pro-
vided no guidance on this issue [6, 8] or have based their 
guidance on the analytic performance of troponin assays, 
recommending the use of a 20% magnitude of change on 
the basis that such a Δ equates to three standard devia-
tions of the troponin assay’s analytic variation [7]. Based 
on the within-person coefficient of variation estimated in 
our study, a 20% change in serial troponin concentrations 
would only have a 90% degree of statistical confidence for 
excluding biological and analytic variation, and would 
therefore not be sufficiently specific for excluding biologi-
cal variation.
Impact of dialysis therapy and cardiac 
 co-morbidity on biological variation
The weekly and monthly within-person variation of 
hs-cTnT estimated from dialysis patients in this study was 
markedly smaller than corresponding values reported 
for healthy individuals (15% and 31%, respectively) [30], 
but similar to those reported for non-dialysis dependent 
individuals with coronary artery disease (7.3% at 4-hourly 
intervals and 10.7% at 3-weekly intervals) [31]. These 
findings are likely explained by the fact that both dialy-
sis patients and non-dialysis dependent patients with 
coronary artery disease have baseline troponin-T concen-
trations around or exceeding the 99th centile upper refer-
ence limit of the hs-cTnT assay [16, 31] whereas healthy 
individuals have much lower baseline values [11]. Accord-
ingly, any fluctuations in troponin concentrations caused 
by biological variation in the former groups represent a 
smaller proportion of the baseline concentration resulting 
in a smaller within-person coefficient of variation.
In our study the within-person coefficient of varia-
tion of hs-cTnT was not significantly different between 
dialysis modalities, by ischaemic heart disease status, 
by severity of diastolic dysfunction, or across quartiles of 
baseline hs-cTnT concentrations implying that the refer-
ence change values described previously can be applied to 
dialysis patients regardless of their cardiac co-morbidity 
status or dialysis modality. Furthermore, the analytic vari-
ation in our study was consistent with that reported from 
a multi-centre evaluation of the same analytic method 
using standard laboratory protocols [11]. It is therefore 
unlikely that the reference change values reported in this 
study would be appreciably affected by analytic differ-
ences related to ‘real world’ performance of the hs-cTnT 
assay.
Strengths and limitations
Our estimates of the within-person variation of hs-cTnT in 
the dialysis population are supported by the findings of 
Aakre et al. [32], Pianta et al. [16] and Jacobs et al. [33] who 
reported a within-person coefficient of variation of 8.3%, 
9.7% and 13% for hs-cTnT measured weekly, fortnightly 
and monthly, respectively, in haemodialysis patients. 
However, these studies were limited by the exclusion 
of peritoneal dialysis patients [16, 32, 33], a paucity of 
repeated measures [16, 33] and most importantly by a lack 
of rigour in ensuring patient stability, wherein they relied 
either on patient report [16] or a history of hospitalisation 
[32, 33] alone to determine stability. The latter introduces 
the possibility that unstable patients may have been 
included in the analyses of these studies and impacted the 
accuracy of their findings. Indeed, Aakre et  al. reported 
that hs-cTnT concentrations measured over 90-min inter-
vals in their study demonstrated a consistent decreasing 
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trend; this may reflect recovering acute myocardial injury 
due to haemodialysis-induced cardiac stunning [34] 
which was not considered by the authors [32].
Our study has a number of important strengths that 
address these limitations, including the enrolment of 
both peritoneal- and haemo-dialysis patients, multi-
ple measurements of hs-cTnT, and a rigorous approach 
towards ensuring stability of all factors affecting hs-cTnT 
concentrations.
Nevertheless, the present study has several limita-
tions. First, patients with the most severe cardiovascular 
co-morbidities were excluded to maximise the likelihood 
that enrolled patients would remain stable for the dura-
tion of follow-up. Although this potentially limits the 
generalisability of the study’s findings, it is noteworthy 
that the baseline characteristics of our study cohort were 
similar to those reported for prevalent Australasian dialy-
sis patients in the Australian and New Zealand Dialysis 
and Transplant Registry [35]. Second, the biological vari-
ation of hs-cTnT over 3-hourly intervals was not investi-
gated. While this would have most closely approximated 
the interval over which hs-cTnT is measured in clinical 
practice, such a study design would have imposed sub-
stantial inconvenience on participants, necessitating a 
15-h visit and five venepunctures on a non-dialysis day 
and would likely have limited participation. Finally, our 
study could not determine if the within-person coefficient 
of variation of hs-cTnT was affected by left ventricular sys-
tolic impairment as only one such patient remained stable 
during the study.
Conclusions
Based on the findings of this study, it is recommended that 
hs-cTnT concentrations measured in dialysis patients for 
the diagnosis of acute myocardial injury be interpreted 
using a relative change strategy rather than by compar-
ing absolute concentrations to a reference interval. An 
increase of over 33% or a reduction of 25% in serial hs-cTnT 
concentrations measured at weekly intervals from dialysis 
patients excludes change due to biological and analytic 
variation alone with 99% certainty and should prompt 
investigation for coronary and/or non-coronary causes of 
acute myocardial injury; concurrent clinical assessment 
remains essential to establishing the underlying cause of 
acute myocardial injury and to guide therapy accordingly. 
Using the change limits identified in this study, future ran-
domised studies should investigate if early intervention 
for minor, but significant, changes in cardiac troponin 
concentrations improves patient outcomes in the dialysis 
population as has been demonstrated in the non-dialysis 
population [36].
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